Pharmaceutical

Immune-Onc’s antibody therapy collects second FDA orphan designation

The company’s monoclonal antibody therapy, IO-202, has received its second orphan drug designation as a treatment for a blood cancer, CMML.

Feb 22, 2024 - 18:00
Immune-Onc’s antibody therapy collects second FDA orphan designation
The company’s monoclonal antibody therapy, IO-202, has received its second orphan drug designation as a treatment for a blood cancer, CMML.
Read the original article

Tags:

Previous Article

Harmony wins orphan drug tag for pitolisant to treat Prader-Willi syndrome 

Next Article

United Therapeutics sues FDA over handling of Liquidia’s NDA

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

How abortion access changed in the first year after Roe v. Wade, in 8 charts

How abortion access changed in the first year after Roe...

Jun 24, 2023

STAT+: FDA expands approval of CRISPR-based medicine to treat beta thalassemia

STAT+: FDA expands approval of CRISPR-based medicine to...

Jan 16, 2024

Nestlé divests peanut allergy treatment Palforzia to Stallergenes Greer

Nestlé divests peanut allergy treatment Palforzia to St...

Sep 5, 2023